Cosentyx is a medication used to treat various inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the drug patent watch website, Cosentyx is available in two formulations, a 150 mg/mL solution for injection and a 150 mg/mL prefilled pen. [1]

The recommended dosage of Cosentyx is 300 mg administered by subcutaneous injection, which is divided into two 150 mg injections, given at different injection sites. The initial dose of Cosentyx is usually given at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 300 mg every 4 weeks thereafter. [2]

The level ranges of Cosentyx are not specifically mentioned in the sources provided. However, a clinical study conducted on the efficacy and safety of Cosentyx in treating psoriasis found that patients treated with Cosentyx had a significant improvement in their psoriasis area and severity index (PASI) scores compared to the placebo group. [3]

The European Medicines Agency (EMA) has reported that the recommended dose of Cosentyx for psoriasis is 300 mg every 4 weeks, while the recommended dose for psoriatic arthritis and ankylosing spondylitis is 150 mg every 4 weeks. [4]

In conclusion, while the specific level ranges of Cosentyx are not mentioned in the sources provided, the recommended dosage for the medication is 300 mg administered by subcutaneous injection, which is divided into two 150 mg injections, given at different injection sites. The recommended dose for psoriasis is 300 mg every 4 weeks, while the recommended dose for psoriatic arthritis and ankylosing spondylitis is 150 mg every 4 weeks. [2][4]

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320967/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108508/
[4] https://www.ema.europa.eu/en/documents/assessment-report/cosentyx-epar-public-assessment-report_en.pdf